This example shows a subset of published controlled terminology parameters and the relationship of values across response variables TSVAL, TSVALNF, TSVALCD, TSVCDREF, and TSVCDVER. Text over 200 characters can be added to additional columns TSVAL1-TSVALn. This example include the subset of terms that are CDISC and FDA required. When required items are not applicable TSVALNF may be used.
TSVALNF contains a “null flavor,” a value that provides additional coded information when TSVAL is null. For example, for TSPARM = "AGEMAX" (Planned Maximum Age of Subjects), there is no value if a study does not specify a maximum age. In this case, the appropriate null flavor is "PINF", which stands for "positive infinity." In a tobacco study conducted in healthy volunteers for a drug where the Trial Phase Classification is not established the null flavor for TSPARM = "TPHASE" would be "NA" (i.e., not applicable). TSVALNF can also be used in a case where the value of a particular parameter is unknown.
ts.xpt
ts.xpt
Row
STUDYID
DOMAIN
TSSEQ
TSGRPID
TSPARMCD
TSPARM
TSVAL
TSVAL1
TSVALNF
TSVALCD
TSVCDREF
TSVCDVER
1
XYZ
TS
1
ACTSUB
Actual Number of Subjects
304
2
XYZ
TS
1
ADAPT
Adaptive Design
N
3
XYZ
TS
1
ADDON
Added on to Existing Treatments
Y
C49487
CDISC CT
2011-06-10
4
XYZ
TS
1
AGEMAX
Planned Maximum Age of Subjects
PINF
5
XYZ
TS
1
AGEMIN
Planned Minimum Age of Subjects
P18M
ISO 8601
6
XYZ
TS
1
PA
DCUTDTC
Data Cutoff Date
2010-04-10
ISO 8601
7
XYZ
TS
1
PA
DCUTDESC
Data Cutoff Description
PRIMARY ANALYSIS
8
XYZ
TS
1
FCNTRY
Planned Country of Investigational Sites
USA
ISO 3166-1 Alpha-3
9
XYZ
TS
2
FCNTRY
Planned Country of Investigational Sites
CAN
ISO 3166-1 Alpha-3
10
XYZ
TS
1
HLTSUBJI
Healthy Subject Indicator
NA
C48660
CDISC CT
2011-06-10
11
XYZ
TS
1
INDIC
Trial Disease/Condition Indication
Tobacco smoking consumption
266918002
SNOMED
2011-03
12
XYZ
TS
1
LENGTH
Trial Length
P3M
ISO 8601
13
XYZ
TS
1
NARMS
Planned Number of Arms
3
14
XYZ
TS
1
OBJPRIM
Trial Primary Objective
Change in concentration of Nicotine in urine from baseline
15
XYZ
TS
1
OBJSEC
Trial Secondary Objective
Change in concentration of Cotinine in urine from baseline
16
XYZ
TS
1
PLANSUB
Planned Number of Subjects
300
17
XYZ
TS
1
RANDOM
Trial is Randomized
Y
C49488
CDISC CT
2011-06-10
18
XYZ
TS
1
REGID
Registry Identifier
NCT123456789
NCT123456789
ClinicalTrials.gov
19
XYZ
TS
2
REGID
Registry Identifier
XXYYZZ456
XXYYZZ456
EudraCT
20
XYZ
TS
1
SENDTC
Study End Date
2011-04-01
ISO 8601
21
XYZ
TS
1
SEXPOP
Sex of Participants
BOTH
C49636
CDISC CT
2011-06-10
22
XYZ
TS
1
SPONSOR
Clinical Study Sponsor
Pharmaco
123456789
D-U-N-S NUMBER
23
XYZ
TS
1
STOPRULE
Study Stop Rules
NONE
24
XYZ
TS
1
TITLE
Trial Title
A 3 month study of tobacco biomarkers in subjects using ENDS devices
25
XYZ
TS
1
TBLIND
Trial Blinding Schema
DOUBLE BLIND
C15228
CDISC CT
2011-06-10
26
XYZ
TS
1
TCNTRL
Control Type
ACTIVE
C49649
CDISC CT
2011-06-10
27
XYZ
TS
1
TITLE
Trial Title
A 3 month study of tobacco biomarkers in subjects using ENDS devices
28
XYZ
TS
1
TDIGRP
Diagnosis Group
NA
29
XYZ
TS
1
INDIC
Trial Disease/Condition Indication
Tobacco smoking consumption
266918002
SNOMED
2011-03
30
XYZ
TS
1
TINDTP
Trial Intent Type
NA
C49656
CDISC CT
2011-06-10
31
XYZ
TS
1
TITLE
Trial Title
A 3 month study of tobacco biomarkers in subjects using ENDS devices
32
XYZ
TS
1
TPHASE
Trial Phase Classification
NA
33
XYZ
TS
1
TTYPE
Trial Type
TOBACCO PRODUCT EFFECT
xxxxxx
CDISC CT
xxxxxxxxx
34
XYZ
TS
2
TTYPE
Trial Type
SAFETY
35
XYZ
TS
3
TTYPE
Trial Type
PHARMACOKINETIC
36
XYZ
TS
1
SDTIGVER
SDTM IG Version
3.4
37
XYZ
TS
2
STDMVER
SDTM Version
1.4
38
XYZ
TS
3
TIGVER
Tobacco IG Version
1.0
Dataset Debug Message
There are three leading, trailing, or non-breaking spaces in the dataset.